Directed Systems, an innovative medical software company, headquartered in Cambridge is proud to announce the receipt of a National Institute for Health and Care Research (NIHR) grant under the i4i Connect program. This 12-month project aims to adapt and validate Directed Systems’ Hypotension Decision Assist (HDA) software for use within the NHS, enhancing patient care during surgery.
Intra-operative hypotension – low blood pressure – (IOH) is a critical concern for patients undergoing anaesthesia during surgery, leading to potential complications such as kidney injuries, strokes, and heart attacks. Directed Systems’ HDA technology is designed to assist anaesthetists in predicting and managing IOH, providing real-time, evidence-based guidance to improve outcomes and reduce post-operative complications and costs.
The NIHR grant will support Directed Systems in collaboration with Professor Tom Clutton-Brock and the NIHR HealthTech Research Centre in Devices, Digital and Robotics (HRC-DDR) at University Hospitals Birmingham NHS Foundation Trust. The project focuses on adapting the HDA software to obtain CE and UKCA regulatory approvals, meet NHS digital standards and integrate seamlessly into NHS workflows.
“We are thrilled to have NIHR’s support and the opportunity to work with Professor Clutton-Brock and his team. This grant allows us to adapt our Hypotension Decision Assist software for the NHS, aiming to reduce surgical complications and improve patient outcomes,” said Mark Leaning, PhD, CEO of Directed Systems.
“The NIHR HRC-DDR is delighted to be able to continue its long and successful relationship with Directed Systems. HDA has the very real potential to reduce mortality, complications and costs in patients undergoing major surgery in the NHS,” said Professor Tom Clutton-Brock, MBE, Clinical Director of the NIHR HRC-DDR.
The project aligns with Directed Systems’ commitment to improving cardiovascular care through innovation, data analytics, and AI-driven insights. It is anticipated that this project will pave the way for wider adoption of HDA technology within the NHS, offering a scalable solution to a pervasive clinical challenge.
